Clinicopathological features of renal amyloidosis: A single-center study on 47 cases

Abstract

The correlations between the clinicopathological features and the long-term outcomes of renal amyloidosis (RA) were analyzed with a view to develop strategies for improving diagnosis and prognosis of RA. We retrospectively reviewed the clinicopathological characteristics of 47 patients diagnosed with RA between 2004 and 2014 at the Wuhan Union Hospital. The data on the renal histology, clinical manifestations, and prognosis of RA patients were retrieved from the hospital records and characteristic patterns were identified. The histological changes in the kidneys were correlated with the clinical manifestations of RA. Additionally, most RA patients in this study had decreased serum levels of κ light chain and increased urine levels of κ and λ light chains as well as presence of M-protein in the urine and serum. Patients with early RA showed no specific pathognomonic symptoms. Bleeding associated with diagnostic renal biopsy was rare. We recommend that the routine work-up of patients aged over 40 years and presenting with non-diabetic nephropathy includes the non-invasive tests for the measurement of serum and urine levels of κ and λ light chains as well as protein electrophoresis tests for the presence of urinary and serum M-protein. Additionally, such patients should undergo renal biopsy screening with Cong-red staining to ensure early diagnosis of RA and improve their survival, since the risk of hemorrhage related to renal biopsy screening is low at early stages of RA.

Keywords

renal amyloidosis / renal pathology / clinical feature

References

[1] LachmannHJ, HawkinsPN. Systemic amyloidosis. Curr Opin Pharmacol, 2006, 6(2): 214-220 PMID: 16483845

[2] PinneyJH, SmithCJ, TaubeJB, et al. . Systemic amyloidosis in England: An epidemiological study. Br J Haematol, 2013, 161(4): 525-532 PMCID: 4296340 PMID: 23480608

[3] RysavaR. Al amyloidosis with renal involvement. Kidney Blood Press R, 2007, 30(6): 359-364

[4] PickenMM. Amyloidosis-where are we now and where are we heading?. Arch Pathol Lab Med, 2010, 134(4): 545-551 PMID: 20367306

[5] LachmannHJ, BoothDR, BoothSE, et al. . Misdiagnosis of hereditary amyloidosis as al (primary) amyloidosis. N Engl J Med, 2002, 346(23): 1786-1791 PMID: 12050338

[6] LiLS, LiuZH. Epidemiologic data of renal diseases from a single unit in china: Analysis based on 13, 519 renal biopsies. Kidney Int, 2004, 66(3): 920-923 PMID: 15327382

[7] YaoY, ZhangYK, WangSX. AL amyloidosis: clinicopathology and recent advances in therapy. Zhongguo Linchuang Yishi Zazhi (Chinese), 2012, 6(15): 4180-4181

[8] JinB, ZengC, GeY, et al. . The spectrum of biopsy-proven kidney diseases in elderly Chinese patients. Nephrol Dial Transpl, 2014, 29(12): 2251-2259

[9] VerdeE, QuirogaB, RiveraF, et al. . Renal biopsy in very elderly patients: Data from the spanish registry of glomerulonephritis. Am J Nephrol, 2012, 5(3): 230-237

[10] YaoY, WangSX, ZhangYK, et al. . A clinicopathological analysis in a large cohort of Chinese patients with renal amyloid light-chain amyloidosis. Nephrol Dial Transpl, 2013, 28(3): 689-697

[11] SuzukiK. Diagnosis and treatment of multiple myeloma and al amyloidosis with focus on improvement of renal lesion. Clin Exp Nephrol, 2012, 16(5): 659-671 PMCID: 3465548 PMID: 22968855

[12] NasrSH, SaidSM, ValeriAM, et al. . The diagnosis and characteristics of renal heavy-chain and heavy/light-chain amyloidosis and their comparison with renal light-chain amyloidosis. Kidney Int, 2013, 83(3): 463-470 PMID: 23302715

[13] GertzMA. Immunoglobulin light chain amyloidosis. 2013 update on diagnosis, prognosis, and treatment. Am J Hematol, 2013, 88(5): 416-425 PMID: 23605846

[14] AbdallahE, WakedE. Incidence and clinical outcome of renal amyloidosis: A retrospective study. Saudi J Kidney Dis Transpl, 2013, 24(5): 950-958 PMID: 24029260

[15] GertzMA, LacyMQ, DispenzieriA, et al. . Amyloidosis: Diagnosis and management. Clin Lymphoma Myelom, 2005, 6(3): 208-219

[16] VerineJ, MouradN, DesseauxK, et al. . Clinical and histological characteristics of renal aa amyloidosis: A retrospective study of 68 cases with a special interest to amyloid-associated inflammatory response. Hum Pathol, 2007, 38(12): 1798-1809 PMID: 17714761

[17] DemberLM. Emerging treatment approaches for the systemic amyloidoses. Kidney Int, 2005, 68(3): 1377-1390 PMID: 16105087

[18] JazbehS, SaidA, HaddadRY, et al. . Renal amyloidosis. Dis Mon, 2014, 60(10): 489-493 PMID: 25280992

[19] OsawaY, KawamuraK, KondoD, et al. . Renal function at the time of renal biopsy as a predictor of prognosis in patients with primary al-type amyloidosis. Clin Exp Nephrol, 2004, 8(2): 127-133 PMID: 15235929

[20] KumarS, DispenzieriA, LacyMQ, et al. . Serum uric acid: Novel prognostic factor in primary systemic amyloidosis. Mayo Clin Proc, 2008, 83(3): 297-303 PMID: 18315995

[21] MigrinoRQ, HarmannL, ChristensonR, et al. . Clinical and imaging predictors of 1-year and long-term mortality in light chain (al) amyloidosis: A 5-year follow-up study. Heart Vessels, 2013, 29(6): 793-800 PMID: 24141988

[22] DispenzieriA, LacyMQ, KatzmannJA, et al. . Absolute values of immunoglobulin free light chains are prognostic in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. Blood, 2006, 107(8): 3378-3383 PMCID: 1895763 PMID: 16397135

[23] EiroM, KatohT, WatanabeT. Risk factors for bleeding complications in percutaneous renal biopsy. Clin Exp Nephrol, 2005, 9(1): 40-45 PMID: 15830272

[24] FurieB, VooL, McAdamKP, et al. . Mechanism of factor x deficiency in systemic amyloidosis. N Engl J Med, 1981, 304(14): 827-830 PMID: 7207512

[25] SeldinDC, SanchorawalaV. Adapting to al amyloidosis. Haematologica, 2006, 91(12): 1591-1595 PMID: 17145594

[26] KyleRA, LinosA, BeardCM, et al. . Incidence and natural history of primary systemic amyloidosis in olmsted county, minnesota, 1950 through 1989. Blood, 1992, 79(7): 1817-1822 PMID: 1558973